Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.46 |
| ▸ | ATM | Q13315 | 3/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907015 | 0.93 | ROCK2 (0.46) | ROCK2ATMPIK3C3ROCK1PARP14 | |
| SCHEMBL17819472 | 0.92 | ATM (0.46) | ROCK2ATMPIK3C3ROCK1PARP14 | |
| SCHEMBL17820848 | 0.90 | ROCK2 (0.45) | ROCK2ATMPIK3C3ROCK1PARP14 | |
| SCHEMBL17819940 | 0.89 | ATM (0.42) | ROCK2ATMPIK3C3ROCK1CCR2 | |
| SCHEMBL17819675 | 0.86 | ATM (0.43) | ROCK2ATMPIK3C3ROCK1CCR2 | |
| SCHEMBL17819690 | 0.86 | ATM (0.48) | ROCK2ATMPIK3C3PIK3CA | |
| SCHEMBL17907243 | 0.85 | ROCK2 (0.43) | ROCK2ATMROCK1PARP14CCR2 | |
| SCHEMBL17820660 | 0.85 | PIK3C3 (0.49) | ATMPIK3C3PIK3CA | |
| SCHEMBL17820572 | 0.85 | ATM (0.43) | ROCK2ATMPIK3C3ROCK1PARP14 | |
| SCHEMBL17906787 | 0.84 | ATM (0.45) | ROCK2ATMPIK3C3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | ROCK2 395/4885ATM 3209/4885PIK3C3 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.